Form 6-K Agomab Therapeutics NV For: Sep 14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of September 2026
Commission File Number: 001-43098
AgomAb Therapeutics NV
Posthoflei 1/6
2600 Antwerpen
Belgium
Tel: +32 3 318 91 70
(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On September 14, 2026, AgomAb Therapeutics NV (the “Company”) issued a press release titled, “Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study.” A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in this Form 6-K, including Exhibit 99.1, except for the quotes by Philippe Wiesel, Chief Medical Officer, and Toby Maher, M.D., PhD, Professor of Clinical Medicine at Keck School of Medicine of USC, is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-294220).
INDEX TO EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AgomAb Therapeutics NV | ||
| Date: September 14, 2026 | By: | /s/ Tim Knotnerus |
| Tim Knotnerus | ||
| Chief Executive Officer | ||
ATTACHMENTS / EXHIBITS